AUPH Earnings Prediction
The chart below shows how AUPH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AUPH sees a +8.86% change in stock price 10 days leading up to the earnings, and a -0.55% change 10 days following the report. On the earnings day itself, the stock moves by -4.55%. This data can give you a slight idea of what to expect for the next quarter's release.
AUPH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
59.87M
32.76%
-11.66%
Gross Margin
90.73%
3.06%
-0.41%
Operating Margin
22.85%
134.73%
31.85%
Net Margin
2.39%
104.01%
-88.71%
EPS
0.01
105.26%
-90.00%
No Data Available
AUPH Earnings Analysis
Aurinia Pharmaceuticals Inc Corporation (AUPH.O) Earnings Conference Call
Positive
Q4 Revenue Surge: Total revenue for Q4 2024 was $59.9 million, a 33% increase from Q4 2023, indicating strong growth.
Total Revenue Increase: Full-year 2024 total revenue reached $235.1 million, up 34% from 2023, showcasing overall business expansion.
LUPKYNIS Sales Surge: Net product sales of LUPKYNIS for Q4 2024 were $57.6 million, a 36% increase compared to Q4 2023, reflecting successful market penetration.
LUPKYNIS Sales Surge: For the full year 2024, net product sales of LUPKYNIS were $216.2 million, up 36% from 2023, demonstrating consistent demand.
Operational Efficiency Improvement: Cash flow from operations for Q4 2024 was $30.1 million, compared to $14.3 million in Q4 2023, highlighting improved operational efficiency.
Cash Flow Improvement: For the full year 2024, cash flow from operations was $44.4 million, a significant turnaround from cash used in operations in 2023.
Strong Financial Position: The company ended 2024 with $358.5 million in cash and investments, providing a strong financial position for future growth.
Strategic Business Expansion: Aurinia's strategic focus on expanding its business at academic medical centers and targeting key prescriber segments is expected to drive future growth.
LUPKYNIS Sales Impact: The anticipated new ACR lupus nephritis treatment guidelines are expected to positively impact LUPKYNIS sales this year.
AUR200 Development Progress: The company is advancing the development of AUR200, with initial results from a Phase 1 study expected in Q2 2025, indicating ongoing innovation.
Negative
Operating Expenses Decrease: Total operating expenses for Q4 2024 were $61.5 million, which is a decrease from $74.8 million in Q4 2023, but still reflects significant costs associated with strategic restructuring efforts.
Gross Margin Decline: The gross margin for the full year 2024 was 88%, down from 92% in 2023, indicating a decline in profitability despite increased sales.
Net Income Improvement: The company reported a net income of only $1.4 million for Q4 2024, which is a modest improvement from a net loss of $26.9 million in Q4 2023, suggesting ongoing financial challenges.
Rising Operational Costs: The increase in cost of revenue for the full year 2024 to $28.2 million from $14.1 million in 2023 is concerning, as it indicates rising operational costs that could impact future profitability.
Program Development Challenges: The company ceased development of the AUR300 program, which may indicate challenges in their pipeline and a reliance on fewer products for growth.
AUPH FAQs
How does AUPH typically perform around its earnings report dates?
Is Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AUPH Earning Call Sentiment
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript
AUPH.O
-1.69%Positive
The earnings call shows strong financial performance with significant revenue growth and a move to profitability. A successful restructuring initiative has reduced costs, and a share repurchase program indicates confidence in the company's future. However, management's reluctance to provide long-term guidance and specific data on AUR200 creates some uncertainty. Despite these concerns, the overall sentiment is positive due to record revenue, improved financial health, and strategic focus on high-growth areas.
